Pharmacokinetic models for propofol- Defining and illuminating the devil in the detail

British Journal of Anaesthesia

Volumn 103, Issue 1, 2009, Pages 26-37

  Absalom, A R ^a   Mani, V ^b   De Smet, T ^c   Struys, M M R F ^d  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c Demed Engineering   (Belgium)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Drug delivery, computerized; Drug delivery, infusion; Equipment, infusion systems; Pharmacokinetics, models; Pharmacokinetics, propofol

Indexed keywords

ISOFLURANE; PROPOFOL; INTRAVENOUS ANESTHETIC AGENT;

BLOOD LEVEL; BODY HEIGHT; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG TARGETING; INFUSION RATE; LEAN BODY WEIGHT; MORBID OBESITY; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; BIOLOGICAL MODEL; BLOOD; COMPUTER ASSISTED DRUG THERAPY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; PHYSIOLOGY;

ANESTHETICS, INTRAVENOUS; BODY HEIGHT; BODY WEIGHT; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PROPOFOL;

EID: 67650708119     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep143     Document Type: Review

References (24)

1. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 1981; 217: 681-5
2. Barvais L, Rausin I, Glen JB, et al. Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth 1996; 10: 877-83
3. Billard V, Gambus PL, Chamoun N, Stanski DR, Shafer SL. A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect. Clin Pharm Ther 1997; 61: 45-58
4. Bouillon T, Shafer SL. Does size matter? Anesthesiology 1998; 89: 557-60
5. Coetzee JF, Glen JB, Wium CA, Boshoff L. Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets. Anesthesiology 1995; 82: 1328-45
6. Davidson JA, Macleod AD, Howie JC, White M, Kenny GN. Effective concentration 50 for propofol with and without 67% nitrous oxide. Acta Anaesth Scand 1993; 37: 458-64
7. De Smet T. Rugloop II. Available from http://www.demed.be (accessed April 27, 2009)
8. Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg 1987; 66: 1256-63
9. Gepts E, Shafer SL, Camu F, et al. Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology 1995; 83: 1194-204
10. James W. Research on obesity. London: Her Majesty's Stationary Office, 1976
11. Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994; 80: 104-22
12. Lemmens HJ, Brodsky JB, Bernstein DP. Estimating ideal body weight-a new formula. Obes Surg 2005; 15: 1082-3
13. Lockwood GG, Dob DP, Bryant DJ, et al. Magnetic resonance spectroscopy of isoflurane kinetics in humans. Part I: Elimination from the head. Br J Anaesth 1997; 79: 581-5
14. Lockwood GG, Dob DP, Bryant DJ, et al. Magnetic resonance spectroscopy of isoflurane kinetics in humans. Part II: Functional localization. Br J Anaesth 1997; 79: 586-9
15. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991; 67: 41-8
16. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997; 86: 10-21
17. Minto CF, Schnider TW, Gregg KM, Henthorn TK, Shafer SL. Using the time of maximum effect-site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology 2003; 99: 324-33
18. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharma-codynamics of remifentanil. II. Model application. Anesthesiology 1997; 86: 24-33
19. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacoki-netics of propofol in adult volunteers. Anesthesiology 1998; 88: 1170-82
20. Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol pharmacodynamics. Anesthesiology 1999; 90: 1502-16
21. Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78: 657-65
22. Shafer S. Stanpump. Available from http://opentci.org/ doku.php?id=code:code (accessed April 27, 2009)
23. Struys MM, De Smet T, Depoorter B, et al. Comparison of plasma compartment versus two methods for effect compartment-controlled target-controlled infusion for propofol. Anesthesiology 2000; 92: 399-406
24. Swinhoe CF, Peacock JE, Glen JB, Reilly CS. Evaluation of the predictive performance of a 'Diprifusor' TCI system. Anaesthesia 1998; 53: 61-7